Corticosteroid-induced pancreatitis in patients with autoimmune bullous disease: case report and prospective study.
Corticosteroid pulse therapy using very high doses may produce corticosteroid-induced pancreatitis (CIP) that is unexpected during conventional oral corticosteroid therapy and may sometimes be fatal. Our goal was to evaluate the relation between pulse corticosteroid administration and pancreatitis. A case of CIP is reported, and a prospective study was performed. Corticosteroid pulse therapy followed by 30 mg prednisolone orally was utilized in 7 hospitalized patients with autoimmune bullous disease, and serum pancreatic enzymes were measured during therapy. The case report revealed reproducible pancreatitis in a dose-dependent manner after 2 corticosteroid regimens. In the prospective study, serum pancreatic enzyme levels increased significantly within several days after pulse therapy, then decreased with tapering of the dose of oral prednisolone. Laboratory pancreatic alterations appear to be induced within days after pulse corticosteroid administration in a dose-dependent manner: less than 25 mg of oral prednisolone may be below threshold to alter the pancreatic enzyme level.
Department of Dermatology, Saitama Medical Center, Saitama Medical School, Saitama, Japan. yyusuke@cc.mbn.or.jp
Y
Y
Yoshizawa
S
S
Ogasa
S
S
Izaki
K
K
Kitamura
D000305:Adrenal Cortex Hormones / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000681:Amylases / Q000097:blood / Q000187:drug effects; D000704:Analysis of Variance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010196:Pancreatic Elastase / Q000097:blood / Q000187:drug effects; D010195:Pancreatitis / Q000139:chemically induced*; D010391:Pemphigoid, Bullous / Q000188:drug therapy*; D011239:Prednisolone / Q000627:therapeutic use; D011446:Prospective Studies
D000305:Adrenal Cortex Hormones; D011239:Prednisolone; D000681:Amylases; D010196:Pancreatic Elastase